Today, researchers at the University of Missouri, in collaboration with Immerge BioTherapeutics, a biotechnology company in Charlestown, Mass., announced that they had created four cloned miniature pigs, each lacking one of two copies of the crucial gene.
egfp-vas + and egfp-vas Δ617, which were previously generated (Johnstone and Lasko, 2004), and all the N-terminally deleted egfp-vas constructs were based on a cDNA clone that lacks one copy of a 39 nucleotide tandem repeat, encoding amino acids 141-153 (Lando Ashburnerrner, 1988).
On Wednesday, PPL Therapeutics, the Scottish company that helped create Dolly, the cloned sheep, said it had cloned five pigs that lack one copy of the gene.
One of our important findings was that mice bearing subcutaneous tumours from CT26 and SW620 clones lacking Smad4 were resistant to 5-FU treatment and the overall survival of these mice was poor.
Clones lacking either of these features were eliminated.
While the majority of clones with five cells or less contain one or more basal cells, a few small clones lack basal cells altogether suggesting basal progenitors are able to undergo terminal division leading to clone loss.
However, these expanded clones lacked obvious common structural motifs that would imply the presence of an antigen drive by one or a few peptide autoantigens.
Less than 1% of the clones lacked cDNA inserts (85/12,199).
All three of the interacting Mrg15 cDNA inserts contain the C-terminal MRG domain while one clone is lacking the entire N-terminal chromodomain, suggesting that the MRG domain is sufficient for the interaction with Cap-H2.
